Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is:
- To assess the efficacy of Nova22007, a cyclosporine A (CsA), 0.05% and 0.1% versus
vehicle in patients with vernal keratoconjunctivitis (VKC) after a 4-week treatment
period.
The secondary objectives of this study are:
- To compare the safety and ocular tolerance of Nova22007 0.05% and 0.1%;
- To assess the long term safety and ocular tolerance of Nova22007 0.05% and 0.1%; and
- To assess the decrease in frequency of concomitant artificial tears use.